(Etrolizumab)Biosimilar Reference Antibody-GS40247

货号：GS40247

Etrolizumab (development code RG7413) was an investigational, humanized monoclonal IgG1 antibody developed for the treatment of moderate-to-severe ulcerative colitis (UC) and Crohn's disease (CD). It functioned as a selective anti-integrin therapy, specifically designed to inhibit the migration of a subset of gut-homing lymphocytes into the inflamed intestinal tissue. Unlike broader-spectrum anti-integrins, etrolizumab was engineered to have dual specificity: it binds to the β7 subunit of integrins, thereby blocking both the α4β7 and αEβ7 integrin heterodimers. This dual blockade aimed to inhibit two distinct but complementary pathways of leukocyte trafficking and retention in the gut, potentially offering a more comprehensive anti-inflammatory effect in inflammatory bowel disease (IBD).